Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · JANX · as of Sep 30, 2025
Ownership Breakdown
181
Institutional Holders
▼ 2 vs Q2
$1.59B
Total Inst. Value
▲ $78.48M vs Q2
60.98M
Shares Outstanding
freeFloat 93.82%
65.17M
13F Shares Held
▼ 287,613 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
JANX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 11.19M | 18.08% | 18.08% | $273.48B | Nov 14, 2025 | — held |
FMR LLC pharmaceutical preparations | 9.06M | 14.63% | 14.63% | $221.33B | Nov 13, 2025 | ▲ 167.3K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 4.70M | 7.59% | 7.59% | $114.99B | Nov 14, 2025 | ▲ 240.8K |
BLACKROCK, INC. pharmaceutical preparations | 3.73M | 6.03% | 6.03% | $91.19B | Nov 12, 2025 | ▲ 328.1K |
PARADIGM BIOCAPITAL ADVISORS LP pharmaceutical preparations | 2.92M | 4.72% | 4.72% | $71.37B | Nov 14, 2025 | — held |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 2.77M | 4.48% | 4.48% | $67.82B | Nov 14, 2025 | ▲ 250.0K |
VANGUARD GROUP INC pharmaceutical preparations | 2.42M | 3.90% | 3.90% | $59.07B | Nov 7, 2025 | ▲ 227.7K |
STATE STREET CORP pharmaceutical preparations | 1.89M | 3.06% | 3.06% | $46.23B | Nov 14, 2025 | ▲ 503.4K |
ORBIMED ADVISORS LLC pharmaceutical preparations | 1.77M | 2.85% | 2.85% | $43.16B | Nov 14, 2025 | ▲ 555.8K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 1.71M | 2.76% | 2.76% | $41.80B | Nov 14, 2025 | ▼ 433.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+5.15M shares1
New Positions
first time holders14
Decreased
−3.23M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.92M
+5.15M / −3.23M
Net new holders
+16
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
JANX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
1
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr | Jun 2, 2026 | Sale | 4,059 | $14.03 | $56.9K | 75.9K | Form 4 ↗ |
Dobek Maria Vice President, Accounting | May 11, 2026 | Sale | 2,038 | $14.17 | $28.9K | 32.3K | Form 4 ↗ |
Go William Chief Medical Officer | Feb 2, 2026 | Award | 154,000 | $13.99 | $2.15M | 154.0K | Form 4 ↗ |
Go William Chief Medical Officer | Feb 2, 2026 | Award | 44,000 | — | — | 44.0K | Form 4 ↗ |
Meyer Andrew Hollman Chief Business Officer | Jan 2, 2026 | Sale | 1,879 | $13.73 | $25.8K | 83.1K | Form 4 ↗ |
DiRaimondo Thomas Chief Scientific Officer | Jan 2, 2026 | Award | 31,400 | — | — | 155.8K | Form 4 ↗ |
DiRaimondo Thomas Chief Scientific Officer | Jan 2, 2026 | Sale | 2,505 | $13.73 | $34.4K | 124.4K | Form 4 ↗ |
DiRaimondo Thomas Chief Scientific Officer | Jan 2, 2026 | Award | 109,900 | $13.65 | $1.50M | 109.9K | Form 4 ↗ |
Campbell David Alan President and CEO | Jan 2, 2026 | Award | 96,600 | — | — | 381.6K | Form 4 ↗ |
Campbell David Alan President and CEO | Jan 2, 2026 | Award | 338,100 | $13.65 | $4.62M | 338.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Janux Therapeutics, Inc. (JANX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 6.18%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Janux Therapeutics, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 11.19 million shares — equal to 18.08% of outstanding shares — as of September 30, 2025.
A total of 181 institutional investors currently hold JANX stock, with a combined institutional value of approximately $1.59 billion as of the most recent 13F filing period.
Frequently asked questions
JANX ownershipJanux Therapeutics, Inc. (JANX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 18.08% stake. Company insiders hold 6.18%. Data sourced from SEC Form 13F as of September 30, 2025.